News

The phase 2 segment has been designed to assess the safety and immunogenicity of INO-4800 Covid-19 vaccine candidate to confirm the dose for the subsequent efficacy assessment as

These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th – 8th. The oral presentation slides, which include follow-up

SY-2101 represents a strategic opportunity to leverage Syros’ expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical-stage drug candidate that has the

Via its affiliates, the investor Sino Biopharmaceutical has invested around $500m in exchange for about 15% of the total equity interest of Sinovac LS. Earlier to the announcement

Aspartylglucosaminuria (AGU) is an inherited rare, progressively debilitating neurodegenerative lysosomal storage disorder. Currently there are no approved treatments to slow or cure AGU in patients living with this

HMR59 is being developed to administer as a one-time, outpatient and intravitreal injection to protect vision in patients with geographic atrophy, a late-stage and severe form of age-related

These indications were approved under the FDA’s accelerated approval programme based on data from the phase I/II ARROW study. Continued approval for these indications may be contingent upon

PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form

Bamlanivimab recently received emergency use authorization for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.